<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02985983</url>
  </required_header>
  <id_info>
    <org_study_id>4827-006</org_study_id>
    <nct_id>NCT02985983</nct_id>
  </id_info>
  <brief_title>A Study of KHK4827 in Subjects With Axial Spondyloarthritis (axSpA)</brief_title>
  <official_title>A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Efficacy and Safety of KHK4827 in Subjects With Axial Spondyloarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of KHK4827 in axSpA (ankylosing spondylitis [AS] and
      non-radiographic axial spondyloarthritis [nr-axSpA]) subjects compared to placebo, as
      measured by the proportion of axSpA subjects achieving an Assessment of SpondyloArthritis
      international Society (ASAS) 40 response at week 16.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of ASAS 40 in axSpA subjects</measure>
    <time_frame>Week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of ASAS 40 in AS subjects</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of ASAS 40 in nr-axSpA subjects</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP change from baseline in axSpA subjects</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Up to week 68</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients exposed to anti-KHK4827 antibodies</measure>
    <time_frame>Pre-dose,Week 16,Week 32,Week 48,Week 68 or End of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum KHK4827 concentration</measure>
    <time_frame>pre-dose、Week 1、Week 2、Week 4、Week 8、Week 12、Week 14、Week 16、Week 24、Week 28、Week 32</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Axial Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>KHK4827</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KHK4827 administered SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KHK4827</intervention_name>
    <description>Administered KHK4827 by subcutaneous (SC) injection until week 66.</description>
    <arm_group_label>KHK4827</arm_group_label>
    <other_name>Brodalumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered Placebo by subcutaneous (SC) injection until week 16. Administered KHK4827 by SC injection from week 17 until week 66.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject with age at onset &lt;45 years and continuous chronic back pain for ≥ 3 months
             fulfills the ASAS classification criteria of axial spondyloarthritis (with the
             exception of the Crohn's disease)

          -  Subject has Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≥ 4 at
             screening and enrollment

          -  Subject has spinal pain score (BASDAI question #2) ≥ 4 at screening and enrollment

          -  Subject has had adequate therapy with non-steroidal anti-inflammatory drugs (oral
             NSAIDs) for back pain for at least 3 months with inadequate treatment response before
             enrollment

        Exclusion Criteria:

          -  Complete ankylosis (fusion) of the spine

          -  Subject with active ongoing inflammatory diseases other than axSpA that might confound
             the evaluation of KHK4827 therapy, including reactive arthritis, spondyloarthritis
             associated with inflammatory bowel disease, SAPHO syndrome (pustulotic
             arthro-osteitis), fibromyalgia, ankylosing spinal hyperostosis, osteitis condensans
             ilii, spondylosis deformans, or osteoarthritis sacroiliac joint disease

          -  Subject has a prior history of &gt;1 anti-TNF therapy

          -  Subject has a history or evidence of suicidal ideation (severity of 4 or 5) or any
             suicidal behavior based on an assessment with the Columbia-Suicide Severity Rating
             Scale (C-SSRS) at enrollment

          -  Subject has a history or evidence of a psychiatric disorder, alcohol and/or substance
             abuse

          -  Subject has severe depression based on a total score of ≥ 15 on the Patient Health
             Questionnaire-8 (PHQ-8) at enrollment (note: subjects with a total score of 10 to 14
             on the PHQ-8 should be referred to a mental health care professional)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyowa Hakko Kirin Co., Ltd.</last_name>
    <email>clinical.info@kyowa-kirin.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyowa Hakko Kirin Co., Ltd.</last_name>
    </contact>
    <contact_backup>
      <email>clinical.info@kyowa-kirin.co.jp</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyowa Hakko Kirin Co., Ltd.</last_name>
    </contact>
    <contact_backup>
      <email>clinical.info@kyowa-kirin.co.jp</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyowa Hakko Kirin Co., Ltd.</last_name>
    </contact>
    <contact_backup>
      <email>clinical.info@kyowa-kirin.co.jp</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2016</study_first_submitted>
  <study_first_submitted_qc>December 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2016</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brodalumab</keyword>
  <keyword>KHK4827</keyword>
  <keyword>Axial Spondyloarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

